Avenzo Therapeutics
A Californian clinical-stage biotech developing next generation oncology therapeutics.
The company’s lead drug candidate, AVZO-021, is a novel, highly potent and selective inhibitor of CDK2, a key enzyme involved in cell cycle regulation. As of Q1 2024, AVZO-021 is being studied in a Phase I study in the US for the treatment of advanced solid tumors.
Latest Avenzo Therapeutics News & Features
26 March 2024
5 January 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze